Tuberculosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Tuberculosis Pipeline Drugs Market Overview
The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include an overall sensation of feeling unwell, cough, possibly bloody mucus, fatigue, shortness of breath, weight loss, and pain in the chest.
The Tuberculosis pipeline market research report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects.
Tuberculosis Pipeline Products Market Segmentation by Targets
The key targets in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, Mycobacterium tuberculosis Protein Ag85A, 23S Ribosomal RNA, H+ Transporting Two Sector ATPase, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Mycobacterium tuberculosis ESAT 6 Protein EsxA, RNA Polymerase, Transmembrane Transport Protein mmpL3, 16S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH], and others.
Tuberculosis Pipeline Products Market Analysis by Targets
For more target insights into the Tuberculosis pipeline products market, download a free report sample
Tuberculosis Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor, 23S Ribosomal RNA Inhibitor, H+ Transporting Two Sector ATPase Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, RNA Polymerase Inhibitor, Transmembrane Transport Protein mmpL3 Inhibitor, 16S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, Cell Wall Synthesis Inhibitor, DNA Synthesis Inhibitor, and others.
Tuberculosis Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Tuberculosis pipeline products market, download a free report sample
Tuberculosis Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Tuberculosis pipeline products market are oral, inhalational, intramuscular, intradermal, intravenous, parenteral, nasal, subcutaneous, intravesical, sublingual, and topical.
Tuberculosis Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Tuberculosis pipeline products market, download a free report sample
Tuberculosis Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Tuberculosis pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, live attenuated vaccine, inactivated vaccine, cell therapy, DNA vaccine, monoclonal antibody conjugated, mRNA vaccine, and others.
Tuberculosis Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Tuberculosis pipeline products market, download a free report sample
Competitive Landscape
Some of the leading players in the Tuberculosis pipeline products market are GSK plc, Quratis Inc, Vichem Chemie Research Ltd, Chongqing Zhifei Biological Products Co Ltd, Collaborations Pharmaceuticals Inc, Sequella Inc, Bioversys AG, Chengdu Keen Biotechnology Co Ltd, Eli Lilly and Co, and Microbiotix Inc.
Tuberculosis Pipeline Products Market Analysis by Players
To know more about the leading players in the Tuberculosis pipeline products market, download a free report sample
Tuberculosis Pipeline Products Market Report Overview
Key Targets | FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, Mycobacterium tuberculosis Protein Ag85A, 23S Ribosomal RNA, H+ Transporting Two Sector ATPase, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Mycobacterium tuberculosis ESAT 6 Protein EsxA, RNA Polymerase, Transmembrane Transport Protein mmpL3, 16S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH], and Others |
Key Mechanisms of Action | FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor, 23S Ribosomal RNA Inhibitor, H+ Transporting Two Sector ATPase Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, RNA Polymerase Inhibitor, Transmembrane Transport Protein mmpL3 Inhibitor, 16S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, Cell Wall Synthesis Inhibitor, DNA Synthesis Inhibitor, and Others |
Key Routes of Administration | Oral, Inhalational, Intramuscular, Intradermal, Intravenous, Parenteral, Nasal, Subcutaneous, Intravesical, Sublingual, and Topical |
Key Molecule Type | Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, Vaccine, Live Attenuated Vaccine, Inactivated Vaccine, Cell Therapy, DNA Vaccine, Monoclonal Antibody Conjugated, mRNA Vaccine, and Others |
Leading Players | GSK plc, Quratis Inc, Vichem Chemie Research Ltd, Chongqing Zhifei Biological Products Co Ltd, Collaborations Pharmaceuticals Inc, Sequella Inc, Bioversys AG, Chengdu Keen Biotechnology Co Ltd, Eli Lilly and Co, and Microbiotix Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Archivel Farma SL
Astellas Pharma Inc
AstraZeneca Plc
Astria Therapeutics Inc
Atomwise Inc
Austrianni GmbH
BioLingus AG
BioNTech SE
Bioversys AG
Bristol-Myers Squibb Co
C&O Pharmaceutical Technology (Holdings) Ltd
CanSino Biologics Inc
Changzhou Yinsheng Pharmaceutical Co Ltd
Chengdu Keen Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Collaborations Pharmaceuticals Inc
Consegna Pharma Inc
Crestone Inc
Daiichi Sankyo Co Ltd
Demuris Ltd
Eisai Co Ltd
Eli Lilly and Co
Ena Therapeutics Pty Ltd
Enyo Pharma SA
EpiVax Inc
Evotec SE
Exscientia Plc
Eyam Vaccines and Immunotherapeutics Ltd
EyeGene Inc
Fimbrion Therapeutics Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
GC Biopharma Corp
Genu Pharma Co Ltd
Globeimmune Inc
Greffex Inc
GSK plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Egg Biotechnology Co Ltd
HanaVax Inc
Hsiri Therapeutics LLC
ILiAD Biotechnologies LLC
Immodulon Therapeutics Ltd
Immunitor Inc
ImmunoBiology Ltd
Innovare R & D SA De CV
Jiangsu Recbio Technology Co Ltd
L2 Diagnostics LLC
Lead Discovery Center GmbH
LegoChem Biosciences Inc
MannKind Corp
Medicines Development for Global Health Ltd
Merck & Co Inc
MetalloPharm LLC
Microbiotix Inc
Mountain Valley MD Holdings Inc
Mycosynthetix Inc
Nearmedic Plus
Neuro Horizon Pharma LLC
NovoBiotic Pharmaceuticals LLC
NTxBio LLC
Nykode Therapeutics ASA
Opal Biosciences Ltd
Otsuka Pharmaceutical Co Ltd
Pai Life Sciences Inc
Palisades Therapeutics
Pathens Inc
PDS Biotechnology Corp
PeptiDream Inc
Pfizer Inc
Pharmapraxis
Pharmasyntez
Primetime Life Sciences LLC
Protibea Therapeutics Inc
Quratis Inc
QureTech Bio AB
Qurient Co Ltd
Sanofi
Sentan Pharma Inc
Sequella Inc
Serum Institute of India Pvt Ltd
Shanghai H&G Biotech
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Spero Therapeutics Inc
Sphaera Pharma Pte Ltd
Standigm Inc
Target Medicals
Tibet Rhodiola Pharmaceutical Holding Co Ltd
TVAX Biomedical Inc
Tydock Pharma Srl
Uvax Bio LLC
Vaxil Bio Therapeutics Ltd
Vaxinano SE
Vaxine Pty Ltd
Vaxxit Srl
Vichem Chemie Research Ltd
Vir Biotechnology Inc
Zata Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Tuberculosis pipeline products market?
The key targets in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase, Mycobacterium tuberculosis Protein Ag85A, 23S Ribosomal RNA, H+ Transporting Two Sector ATPase, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI, Mycobacterium tuberculosis ESAT 6 Protein EsxA, RNA Polymerase, Transmembrane Transport Protein mmpL3, 16S Ribosomal RNA, Enoyl [Acyl Carrier Protein] Reductase [NADH], and others.
-
What are the key mechanisms of action in the Tuberculosis pipeline products market?
The key mechanisms of action in the Tuberculosis pipeline products market are FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase Inhibitor, 23S Ribosomal RNA Inhibitor, H+ Transporting Two Sector ATPase Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] FabI Inhibitor, RNA Polymerase Inhibitor, Transmembrane Transport Protein mmpL3 Inhibitor, 16S Ribosomal RNA Inhibitor, Enoyl [Acyl Carrier Protein] Reductase [NADH] Inhibitor, Cell Wall Synthesis Inhibitor, DNA Synthesis Inhibitor, and others.
-
What are the key routes of administration in the Tuberculosis pipeline products market?
The key routes of administration in the Tuberculosis pipeline products market are oral, inhalational, intramuscular, intradermal, intravenous, parenteral, nasal, subcutaneous, intravesical, sublingual, and topical.
-
What are the key molecule types in the Tuberculosis pipeline products market?
The key molecule types in the Tuberculosis pipeline products market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, live attenuated vaccine, inactivated vaccine, cell therapy, DNA vaccine, monoclonal antibody conjugated, mRNA vaccine, and others.
-
Who are the leading players in the Tuberculosis pipeline products market?
Some of the leading players in the Tuberculosis pipeline products market are GSK plc, Quratis Inc, Vichem Chemie Research Ltd, Chongqing Zhifei Biological Products Co Ltd, Collaborations Pharmaceuticals Inc, Sequella Inc, Bioversys AG, Chengdu Keen Biotechnology Co Ltd, Eli Lilly and Co, and Microbiotix Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.